参考文献/References:
［1］ Dormandy JA, Rutherford RB. Management of peripheral arterial disease（PAD）. TASC Working Group. TransAtlantic Inter-Society Consensus （TASC）［J］. J Vasc Surg, 2000, 31: S1-S296.
［2］ Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the management of peripheral arterial disease（TASC Ⅱ）［J］. Eur J Vasc Endovasc Surg, 2007, 33 Suppl 1: S1-75.
［3］ Bosiers M, Deloose K, Callaert J, et al. BRAVISSIMO study: 12-month results from the TASC A/B subgroup［J］. J Cardiovasc Surg （Torino）, 2012, 53: 91-99.
［4］ Ratnam L, Raza SA, Horton A, et al. Outcome of aortoiliac, femoropopliteal and infrapopliteal endovascular interventions in lesions categorised by TASC classification［J］. Clin Radiol, 2012, 67: 949-954.
［5］ 王洪剑, 邓 钢, 秦永林, 等． 球囊扩张或（和）支架植入术治疗股浅动脉狭窄或闭塞的中远期疗效［J］． 介入放射学杂志, 2012, 21: 810-815．
［6］ Baril DT, Chaer RA, Rhee RY, et al. Endovascular interventions for TASC II D femoropopliteal lesions［J］. J Vasc Surg, 2010, 51: 1406-1412.
［7］ Ye W, Liu CW, Ricco JB, et al. Early and late outcomes of percutaneous treatment of TransAtlantic Inter-Society Consensus class C and D aorto-iliac lesions［J］. J Vasc Surg, 2011, 53: 1728-1737.
［8］ 高海军， 陈 光， 王 浩， 等． 支架成形联合置管溶栓治疗TASC（Ⅱ）D型主髂动脉闭塞性疾病［J］． 介入放射学杂志， 2012， 21： 948-952．
［9］ 张 韬， 张小明， 张学民， 等． 导管溶栓技术在治疗下肢动脉缺血性疾病中的应用体会［J］． 中华外科杂志， 2011， 49： 859-860．
［10］ Schrijver A, VosJ, Hoksbergen AW, et al. Ultrasound-accelerated thrombolysis for lower extremity ischemia:multicenter experience and literature review［J］. J Cardiovasc Surg（Torino）, 2011, 52:467-476.
［11］ 刘昌伟， 刘 暴． 下肢动脉硬化闭塞症的腔内治疗基本技巧［J］． 中国微创外科杂志， 2011， 11： 13-14．
［12］ Ferraresi R, Palena LM, Mauri G, et al. Tips and tricks for a correct “endo approach”［J］. J Cardiovasc Surg （Torino）, 2013, 54: 685-711.
［13］ 钟红珊， 孟令岩， 徐 克， 等． 股深动脉开通与股浅动脉支架植入治疗下肢缺血的对照研究［J］． 介入放射学杂志， 2013， 22： 283-287．
［14］ Sidhu R, Pigott J, Pigott M, et al. Subintimal angioplasty for advanced lower extremity ischemia due to TASC Ⅱ C and D lesions of the superficial femoral artery［J］. Vasc Endovascular Surg, 2010, 44: 633-637.
［15］ Markose G, Miller FN, Bolia A, et al. Subintimal angioplasty for femoro-popliteal occlusive disease［J］. J Vasc Surg, 2010, 52: 1410-1416.
［16］ Setacci C, Sirignano P, Setacci F. Commentary: Outback catheter in femoropopliteal subintimal angioplasty: new horizons in treating chronic total occlusions［J］. J Endovasc Ther, 2011, 18: 22-24.
［17］ 顾建平， 楼文胜， 徐 克． 加强下肢动脉硬化闭塞症介入治疗的研究［J］． 介入放射学杂志， 2011， 20： 757-759．
［18］ Smith M, Pappy R, Hennebry TA. Re-Entry devices in the treat-ment of peripheral chronic occlusions［J］. Tex Heart Inst J, 2011, 38: 392-397.
［19］ Langhoff R, Stumpe S, Treitl M, et al. Successful revasculariz-ation of chronic total occlusion of lower extremity arteries: a wire only and bail out use of re-entry device approach［J］. J Cardiovasc Surg （Torino）, 2013, 54: 553-559.
［20］ Hendricks NJ, Sabri SS. Subintimal arterial flossing with antegrade-retrograde intervention（SAFARI） and rertograde access for critical limb ischemia［J］. Tech Vasc Interv Radiol, 2014, 17: 203-210.
［21］ Rusyn VV. The hybrid operations for the critical ischemia of the lower extremities［J］. Klin Khir, 2013, 9: 42-46.
［22］ Uchkin IG, Shugushev ZK, Vikhert TA, et al. Peculiarities of performing hybrid operation in a patient with atherosclerosis of lower limbs and developed critical ischaemia［J］. Angiol Sosud Khir, 2013, 19: 165-169.
［23］ Steinbauer M, Katsargyris A, Greindl M, et al. Hybrid operation theatre in vascular surgery. Options and perspectives［J］. Chirurg, 2013, 84: 1030-1035.
［24］ Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO Ⅱ trial［J］. J Vasc Interv Radiol, 2005, 16: 331-338.
［25］ Schneider JR, Verta MJ, Alonzo MJ, et al. Results with Viabahn-Assisted subintimal recanalization for TASC C and TASC D superficial femoral artery occlusive disease［J］. Vasc Endovascular Surg, 2011, 45: 391-397.
［26］ Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial［J］. Circ Cardiovasc Interv, 2012, 5: 831-840.
［27］ Abbott JD, Earl T, Vlachos HE, et al. Direct stenting compared to balloon predilation in drug-eluting stents: one-year outcomes from the DEScover Registry［J］. Catheter Cardiovasc Interv, 2012, 79: 84-89.
［28］ Abdel-Latif A, Moliterno DJ. Creating biodegradable-polymer drug-eluting stents: shortening the duration of polymer and dual antiplatelet therapy while lengthening the follow-up［J］. Catheter Cardiovasc Interv, 2012, 79: 217-218.